The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...

For traditional approval, CAR T therapies will need to establish superiority over current standard treatments, including ...

Background Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) among young individuals and ...

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of ...

Detailed price information for Niagen Bioscience Inc (NAGE-Q) from The Globe and Mail including charting and trades.

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...

Patients undergoing cardiac surgery often receive red-cell transfusions, along with the associated risks and costs. Early intraoperative normovolemic hemodilution (i.e., acute normovolemic ...